甲磺酸左氧氟沙星的药代动力学研究  

The pharmacokinetic study of levofloxacin mesylate

作　　者：任乔林[1] 林赴田[1] 孙涛[1] 宋坤改[1] 赵春燕[1] 刘尚裕[1] 张宇 殷安凡 

机构地区：[1]中国医学科学院中国协和医科大学医药生物技术研究所 [2]北京双鹤药业有限公司

出　　处：《中国抗生素杂志》1999年第3期205-207,238,共4页Chinese Journal of Antibiotics

摘　　要：用微生物法测定了ＭＳＡＬＶＬＸ在狗体内的药代动力学过程符合二室模型。４、８和１６ｍｇ／ｋｇ口服给药的Ｃｍａｘ分别为１．７３、２．８９和８．２８ｍｇ／Ｌ，ＡＵＣ值分别为１５．４３、３１．９５和７０．２ｍｇｈ／Ｌ，ＭＲＴ分别为６．９６、７．５８和６６２８ｈ。大鼠口服２０ｍｇ／ｋｇ的Ｃｍａｘ为２．８６ｍｇ／Ｌ，ｔ１／２β为２．２ｈ，ＡＵＣ为７．４ｍｇｈ／Ｌ，ＭＲＴ为３ｈ。大鼠口服后７２ｈ的尿中排泄率为４２％，而７２ｈ胆汁排泄率为３８．２％。The pharmacokinetics of levofloxacin mesylate (MSALVLX) determined by microbiological assay in dogs fitted with a twocompartment model. Following single oral doses of 4, 8 and 16mg/kg, Cmax were 1.73, 2.89 and 8.28 mg/L respectively; t1/2 were 3￣6h; AUC were 15.43, 31.95 and 8.28 mgh/L respectively; MRT were independent of doses, and corresponding values were 6.96, 7.58 and 6.28 h. After a single oral administration of MSALVLX at a dose of 20mg/kg in rats, Cmax was 2.86 mg/L, t1/2 was 2.2h, AUC was 7.4 mgh/L, MRT was 3h. Accumulative urinary and biliary excretions was 42% and 38.2% within 72h after oral administration in rats.

关 键 词：利复星 MSALVLX 药代动力学 血药浓度 

分 类 号：R978.19[医药卫生—药品] R969.1[医药卫生—药学]